Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Summary

Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer. Bortezomib may interfere with the growth of tumor cells by blocking certain enzymes necessary for tumor cell growth

Timeline

Start

2002-04

Primary completion

2006-03

Completion

—

Outcome

Outcome not reported

Stopped: “Administratively complete.”

Drugs

Indications